Specialty chemical and functional ingredient distributor Brenntag has entered into an exclusive distribution partnership with Lipomed.
Through this agreement, Brenntag will now be responsible for the EMEA-wide distribution of Lipomed's CBD Pure API.
The crystalline powder — which is derived from Cannabis sativa L. — contains more than 98.5% pure cannabidiol (CBD), and is suitable for the treatment of rare diseases.
Obtained through a gentle, low-temperature extraction process, the API contains almost no THC, preservatives or artificial additives.
The ingredient is also suitable for non-intoxicating formulations, as it is not psychoactive.
CBD Pure API is also available in custom formulations, so Brenntag's pharmaceutical clients will have better access to flexible solutions for rare disease management.
“Lipomed’s high purity CBD is a perfect addition to our API portfolio in EMEA," noted Christoph Conrad, Head of Industry Market Management APIs & Supplements at Brenntag Specialties.
"As Brenntag always strives to work with the best and most trustworthy partners and materials of the industry, there could not be a better fit than Lipomed. These products combine natural origin, highest purity, and Swiss pharma expertise."
"We are very proud of the trust and confidence we are receiving with this exclusive partnership, and we are sure that together we will create a significant contribution to the development of the pharmaceutical market in EMEA.”
“We are delighted and proud to join forces with such a reputed and skilled partner as the Brenntag team for the commercialisation and distribution of our Natural CBD Pure API in the EMEA region," added Dr. Athanasios Zikopoulos, CEO of Lipomed AG.
"This marks the beginning of a certainly fruitful cooperation that will benefit both parties and their customers.”
